back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2022-06-29 12:53 Tx date 2022-06-24 |
$BHC
Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.) |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+34,387 vol |
119,715 | |
| Filed 2021-05-03 19:45 Tx date 2021-04-30 |
$BHC
Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.) |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$249,991
+7,645 vol $32.70 each |
85,328 | |
| Filed 2020-05-04 10:55 Tx date 2020-05-01 |
$BHC
Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.) |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+11,037 vol |
77,683 | |
| Filed 2019-05-06 11:33 Tx date 2019-05-03 |
$BHC
Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.) |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$249,981
+10,633 vol $23.51 each |
66,646 | |
| Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
| Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
56,013 | |
| Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
56,417 | |
| Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
42,132 | |
| Filed 2016-08-15 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-08-15 Tx date 2016-08-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$98,600
+4,000 vol $24.65 each |
4,000 | |
| Filed 2016-08-11 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
16,726 | |
| Filed 2016-08-11 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
||
| Filed 2016-08-11 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|